Although the standard procedures for detecting BRAF mutations are DNA-based, IHC has many advantages: IHC requires less tumor tissue, detects BRAFV600E mutations in specimens with low tumor content, and enables visualization of the location of mutated melanoma cells. This evidence concerns the gene BRAF and melanoma.